2020 ASCO Virtual Scientific Meeting*

Download All
May 29-31, 2020; Online at meetings.asco.org/am
Expert faculty review and share their insights and perspectives on key findings in lung cancer presented at the 2020 ASCO Annual Meeting.

Lung Cancer

Slidesets Phase Ib/II Trial of Lurbinectedin Plus Irinotecan in Patients With Advanced Solid Tumors
Slidesets KEYNOTE-604 Final Analysis: Addition of Pembrolizumab to Etoposide and Platinum in Extensive-Stage SCLC
Slidesets CASPIAN: Phase III Study of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC
Slidesets ADJUVANT-CTONG 1104: Final OS Analysis of Phase III Study of Adjuvant Gefitinib vs Chemotherapy in Chinese Patients With Resected EGFR-Mutated NSCLC
Slidesets First-line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced NSCLC: 3-Year Update of CheckMate 227 Part 1
Slidesets CheckMate 9LA: Nivolumab and Ipilimumab Plus 2 Cycles of Platinum-Doublet Chemotherapy vs 4 Cycles Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer
Slidesets Phase II CITYSCAPE: Addition of Tiragolumab, an Anti-TIGIT Antibody, to First-line Atezolizumab in PD-L1–Selected Metastatic NSCLC
Slidesets Phase II DESTINY-Lung01: Interim Analysis of Trastuzumab Deruxtecan in Patients With HER2-Mutated NSCLC
Slidesets Phase III SINDAS: Interim Analysis of First-line EGFR TKI With vs Without SBRT in Patients With EGFR-Mutated Oligometastatic NSCLC
Slidesets Phase II GEOMETRY mono-1: Capmatinib in Patients With NSCLC and High MET Amplification
Slidesets Phase I/II ARROW: Registrational Dataset of RET Inhibitor Pralsetinib (BLU-667) in Patients With Advanced RET Fusion–Positive NSCLC
Slidesets RESILIENT Part 1: Phase II Study of Liposomal Irinotecan After Platinum Chemotherapy in Small-Cell Lung Cancer
Slidesets Phase III ADAURA: Adjuvant Osimertinib vs Placebo After Complete Resection in Patients With Stage IB-IIIA EGFR-Mutated NSCLC
Provided by Clinical Care Options, LLC.
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Pharma
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?